BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 18716396)

  • 1. Durable remission of Sézary syndrome after unrelated bone marrow transplantation by reduced-intensity conditioning.
    Kahata K; Hashino S; Takahata M; Fujisawa F; Kondo T; Kobayashi S; Fujita Y; Shimizu H; Imamura M; Asaka M
    Acta Haematol; 2008; 120(1):14-8. PubMed ID: 18716396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides.
    Molina A; Zain J; Arber DA; Angelopolou M; O'Donnell M; Murata-Collins J; Forman SJ; Nademanee A
    J Clin Oncol; 2005 Sep; 23(25):6163-71. PubMed ID: 16135483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic stem cell transplantation after reduced-intensity conditioning in a patient with T-cell prolymphocytic leukemia: graft-versus-tumor effect and long-term remission.
    de Lavallade H; Faucher C; Fürst S; El-Cheikh J; Vey N; Coso D; Bouabdallah R; Stoppa AM; Gastaut JA; Blaise D; Mohty M
    Bone Marrow Transplant; 2006 Apr; 37(7):709-10. PubMed ID: 16474410
    [No Abstract]   [Full Text] [Related]  

  • 4. [Eradication of adult T-cell leukemia cells and maintenance of remission by the graft-versus-leukemia effect after allogeneic bone marrow transplantation].
    Ota K; Hashino S; Shimizu K; Yonezumi M; Chiba K; Kondo T; Suzuki S; Imamura M; Asaka M
    Rinsho Ketsueki; 2004 Sep; 45(9):1044-7. PubMed ID: 15510833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regression of the tumor after withdrawal of cyclosporine in relapsed extranodal natural killer/T cell lymphoma following allogeneic hematopoietic stem cell transplantation.
    Kako S; Izutsu K; Oshima K; Sato H; Kanda Y; Motokura T; Chiba S; Kurokawa M
    Am J Hematol; 2007 Oct; 82(10):937-9. PubMed ID: 17663389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning for mycosis fungoides and Sezary syndrome.
    Shiratori S; Fujimoto K; Nishimura M; Hatanaka KC; Kosugi-Kanaya M; Okada K; Sugita J; Shigematsu A; Hashimoto D; Endo T; Kondo T; Abe R; Hashino S; Matsuno Y; Shimizu H; Teshima T
    Hematol Oncol; 2016 Mar; 34(1):9-16. PubMed ID: 25312300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis.
    Kröger N; Thiele J; Zander A; Schwerdtfeger R; Kobbe G; Bornhäuser M; Bethge W; Schubert J; de Witte T; Kvasnicka HM;
    Exp Hematol; 2007 Nov; 35(11):1719-22. PubMed ID: 17976523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced-intensity bone marrow transplantation from an alternative unrelated donor for myelodysplastic syndrome of first-donor origin.
    Komeno Y; Kanda Y; Kandabashi K; Kawazu M; Goyama S; Takeshita M; Nannya Y; Niino M; Nakamoto T; Kurokawa M; Tsujino S; Ogawa S; Aoki K; Chiba S; Motokura T; Hirai H
    Am J Hematol; 2003 Mar; 72(3):220-2. PubMed ID: 12605397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
    Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A successful second unrelated BMT (UBMT) from a different unrelated donor to treat ALL that relapsed after the initial UBMT.
    Uehara T; Nakaseko C; Yokota A; Saito Y; Nishimura M
    Am J Hematol; 2002 Sep; 71(1):37-40. PubMed ID: 12221672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Graft-versus-ATLL effect induced by abrupt discontinuation of immunosuppression following allogeneic bone marrow transplantation].
    Hara S; Yokote T; Akioka T; Oka S; Yamano T; Tsuji M; Hanafusa T
    Gan To Kagaku Ryoho; 2005 Jun; 32(6):867-71. PubMed ID: 15984534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mesenchymal stem cells remain host-derived independent of the source of the stem-cell graft and conditioning regimen used.
    Bartsch K; Al-Ali H; Reinhardt A; Franke C; Hudecek M; Kamprad M; Tschiedel S; Cross M; Niederwieser D; Gentilini C
    Transplantation; 2009 Jan; 87(2):217-21. PubMed ID: 19155975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone marrow mammaglobin expression as a marker of graft-versus-tumor effect after reduced-intensity allografting for advanced breast cancer.
    Bregni M; Fleischhauer K; Bernardi M; Pescarollo A; Guggiari E; Lunghi F; Deola S; Scaramuzza S; Re F; Setola E; Monari M; Mazzi B; Servida P; Corradini P; Peccatori J
    Bone Marrow Transplant; 2006 Feb; 37(3):311-5. PubMed ID: 16400340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Allogeneic bone marrow transplantation for chemotherapy-resistant T-prolymphocytic leukemia].
    Okamura K; Ikeda T; Shimakura Y; Yoshiba F; Kishi K; Ando K; Hotta T
    Rinsho Ketsueki; 2005 Jul; 46(7):527-31. PubMed ID: 16440747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic hematopoietic stem cell transplantation using a reduced-intensity conditioning regimen in infants: experience at a single institution in Mexico.
    Llano OG; Perez JC; Rodriguez OC; Guerra CM; Aguirre HG; Garza JL; Rodriguez-Romo L; Almaguer DG
    Pediatr Hematol Oncol; 2008; 25(1):39-47. PubMed ID: 18231953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
    Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides: evidence of a graft-versus-tumor effect.
    Burt RK; Guitart J; Traynor A; Link C; Rosen S; Pandolfino T; Kuzel TM
    Bone Marrow Transplant; 2000 Jan; 25(1):111-3. PubMed ID: 10654025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Sustained molecular remission in an adult patient with Sézary syndrome after peripheral allogeneic stem-cell transplantation].
    Jurkovicova J; Xicoy B; Bielsa I; Arellano A
    Med Clin (Barc); 2011 Mar; 136(7):317-8. PubMed ID: 20462612
    [No Abstract]   [Full Text] [Related]  

  • 20. Impact of AB0-blood group incompatibility on the outcome of recipients of bone marrow transplants from unrelated donors in the Japan Marrow Donor Program.
    Kimura F; Sato K; Kobayashi S; Ikeda T; Sao H; Okamoto S; Miyamura K; Mori S; Akiyama H; Hirokawa M; Ohto H; Ashida H; Motoyoshi K;
    Haematologica; 2008 Nov; 93(11):1686-93. PubMed ID: 18835834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.